Marchex Showcases AI Conversation Intelligence Platform at IFA 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy MCHX?
Source: Newsfilter
- Market Opportunity Identification: Marchex's AI-powered conversation intelligence platform provides franchise brands with clear insights into lead handling and conversion performance, enabling businesses to identify market opportunities and enhance overall revenue and competitive positioning.
- Conversion Rate Improvement: By analyzing customer conversations, Marchex can pinpoint reasons for lead failures and optimize conversion rates across various locations, thereby improving booking outcomes, enhancing customer satisfaction, and driving overall franchise growth.
- Operational Efficiency Optimization: The newly launched Agent Performance Suite measures agent behaviors and provides targeted coaching, helping franchisors reduce performance variability, enhance both human and AI agent performance, and optimize customer experiences to minimize revenue loss.
- Wide Industry Application: Marchex's solutions are applicable across multiple sectors, including home services, automotive, healthcare, and multi-unit retail, showcasing its adaptability and strategic significance in various markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCHX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCHX
About MCHX
Marchex, Inc. provides conversation intelligence platform. The Company harnesses the power of artificial intelligence (AI) and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics. The Company’s product offerings include Marketing Edge, Sonar Business Text Messaging, Marchex Platform Services, Spotlight, Engage, Call Summary and Sentiment Suite, and AI for Industry Solution. Marketing Edge leverages conversational intelligence with generative AI to form a comprehensive marketing attribution and conversation data solution. Sonar Business Text Messaging is an AI empowered, intelligent workflow enabled mobile messaging solution that enables operations, sales and marketing teams to communicate personally with field staff, prospects and customers. Marchex Platform Services a robust application programming interface (API) for conversation intelligence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Marchex Reports Q4 2025 Earnings Miss with Significant Losses
- Earnings Report Disappointment: Marchex's Q4 2025 non-GAAP EPS of -$0.04 misses expectations by $0.03, indicating ongoing pressure on the company's profitability.
- Revenue Decline: The fourth quarter revenue of $10.8 million represents a 9.4% year-over-year decrease, falling short of expectations and reflecting weakened market demand and intensified competition.
- Adjusted EBITDA Loss: The adjusted EBITDA loss of $1.2 million for Q4 2025 is significantly higher than the $0.4 million loss reported in Q4 2024, highlighting challenges in cost management.
- Impact of Reorganization Costs: The 2025 adjusted EBITDA loss includes $1.6 million in reorganization and historical acquisition-related costs, but excluding these would result in a $0.4 million gain, suggesting potential profitability in core operations.
See More
Marchex Reports 2025 Financial Results: Revenue Decline Amid AI Transition
- Revenue Decline: In Q4 2025, GAAP revenue was $10.8 million, down 9.2% from $11.9 million in Q4 2024, with total revenue for 2025 at $45.4 million, a 6.1% decrease from $48.1 million in 2024, indicating pressure in market competitiveness.
- Increased Net Loss: The net loss for Q4 2025 was $2.3 million, or $0.05 per share, widening from a $1.9 million loss and $0.04 per share in Q4 2024, with a total annual net loss of $5.2 million, reflecting challenges faced during the transition.
- Adjusted EBITDA Performance: Adjusted EBITDA for Q4 2025 was a loss of $1.2 million, significantly worse than the $0.4 million loss in Q4 2024, although excluding reorganization costs would yield a $0.4 million gain, indicating ongoing cost challenges during the transition.
- AI Transition Outlook: Marchex aims to accelerate revenue growth in 2026, anticipating sequential revenue increases in Q2 compared to Q1, with adjusted EBITDA potentially exceeding $500,000, showcasing confidence in leveraging AI technology for future growth.
See More
MARCHEX INC Reports Q4 Net Loss of $2.3 Million, Equivalent to $0.05 Per Diluted Share
- Financial Performance: MARCHEX INC reported a net loss of $2.3 million for Q4.
- Earnings Per Share: The loss translates to $0.05 per diluted share.
See More
MARCHEX INC Reports Q4 GAAP Revenue of $10.8 Million
- Company Overview: MARCHEX INC reported a revenue of $10.8 million for Q4, indicating its financial performance during this period.
- Financial Highlights: The revenue figure reflects the company's ongoing operations and market position within its industry.
See More
Marchex to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Marchex announced it will release its Q4 and full year 2025 financial results on March 25, 2026, at approximately 4:20 p.m. ET, reflecting the company's commitment to transparency and investor communication.
- Conference Call Discussion: Following the earnings release, management will hold a conference call at 5:00 p.m. ET on the same day to discuss the financial results and company outlook, aiming to bolster investor confidence in the company's future direction.
- Webcast Availability: The call will be available via live webcast on the company's investor website, with an archived version accessible two hours post-call, ensuring that investors unable to attend live can still access critical information.
- Strategic Positioning: Marchex leverages AI and conversational intelligence to drive operational excellence and revenue acceleration, showcasing its leadership in the B2B2C market and emphasizing its ability to optimize customer experiences through data analytics.
See More
PDS Health Leverages AI to Enhance Marketing Performance
- Cost Reduction: PDS Health has reduced its marketing cost per lead by approximately 20% through Marchex's AI signals, optimizing media spend allocation and enhancing overall marketing efficiency.
- Enhanced Engagement: By leveraging Marchex's conversation analytics, PDS Health gains deeper insights into customer engagement trends and conversion signals, effectively tracking and analyzing the impact of customer acquisition campaigns across multiple marketing channels.
- Privacy Compliance Assurance: The Marchex platform delivers actionable marketing intelligence while ensuring adherence to privacy and compliance standards, enabling healthcare organizations to balance performance visibility with patient information protection.
- Improved Decision Support: The marketing team at PDS Health connects engagement signals with appointment outcomes using Marchex's integrated systems, allowing for more informed investment decisions and improved patient experience.
See More
Marchex Reports Q4 2025 Earnings Miss with Significant Losses
- Earnings Report Disappointment: Marchex's Q4 2025 non-GAAP EPS of -$0.04 misses expectations by $0.03, indicating ongoing pressure on the company's profitability.
- Revenue Decline: The fourth quarter revenue of $10.8 million represents a 9.4% year-over-year decrease, falling short of expectations and reflecting weakened market demand and intensified competition.
- Adjusted EBITDA Loss: The adjusted EBITDA loss of $1.2 million for Q4 2025 is significantly higher than the $0.4 million loss reported in Q4 2024, highlighting challenges in cost management.
- Impact of Reorganization Costs: The 2025 adjusted EBITDA loss includes $1.6 million in reorganization and historical acquisition-related costs, but excluding these would result in a $0.4 million gain, suggesting potential profitability in core operations.
See More
Marchex Reports 2025 Financial Results: Revenue Decline Amid AI Transition
- Revenue Decline: In Q4 2025, GAAP revenue was $10.8 million, down 9.2% from $11.9 million in Q4 2024, with total revenue for 2025 at $45.4 million, a 6.1% decrease from $48.1 million in 2024, indicating pressure in market competitiveness.
- Increased Net Loss: The net loss for Q4 2025 was $2.3 million, or $0.05 per share, widening from a $1.9 million loss and $0.04 per share in Q4 2024, with a total annual net loss of $5.2 million, reflecting challenges faced during the transition.
- Adjusted EBITDA Performance: Adjusted EBITDA for Q4 2025 was a loss of $1.2 million, significantly worse than the $0.4 million loss in Q4 2024, although excluding reorganization costs would yield a $0.4 million gain, indicating ongoing cost challenges during the transition.
- AI Transition Outlook: Marchex aims to accelerate revenue growth in 2026, anticipating sequential revenue increases in Q2 compared to Q1, with adjusted EBITDA potentially exceeding $500,000, showcasing confidence in leveraging AI technology for future growth.
See More
MARCHEX INC Reports Q4 Net Loss of $2.3 Million, Equivalent to $0.05 Per Diluted Share
- Financial Performance: MARCHEX INC reported a net loss of $2.3 million for Q4.
- Earnings Per Share: The loss translates to $0.05 per diluted share.
See More
MARCHEX INC Reports Q4 GAAP Revenue of $10.8 Million
- Company Overview: MARCHEX INC reported a revenue of $10.8 million for Q4, indicating its financial performance during this period.
- Financial Highlights: The revenue figure reflects the company's ongoing operations and market position within its industry.
See More
Marchex to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Marchex announced it will release its Q4 and full year 2025 financial results on March 25, 2026, at approximately 4:20 p.m. ET, reflecting the company's commitment to transparency and investor communication.
- Conference Call Discussion: Following the earnings release, management will hold a conference call at 5:00 p.m. ET on the same day to discuss the financial results and company outlook, aiming to bolster investor confidence in the company's future direction.
- Webcast Availability: The call will be available via live webcast on the company's investor website, with an archived version accessible two hours post-call, ensuring that investors unable to attend live can still access critical information.
- Strategic Positioning: Marchex leverages AI and conversational intelligence to drive operational excellence and revenue acceleration, showcasing its leadership in the B2B2C market and emphasizing its ability to optimize customer experiences through data analytics.
See More
PDS Health Leverages AI to Enhance Marketing Performance
- Cost Reduction: PDS Health has reduced its marketing cost per lead by approximately 20% through Marchex's AI signals, optimizing media spend allocation and enhancing overall marketing efficiency.
- Enhanced Engagement: By leveraging Marchex's conversation analytics, PDS Health gains deeper insights into customer engagement trends and conversion signals, effectively tracking and analyzing the impact of customer acquisition campaigns across multiple marketing channels.
- Privacy Compliance Assurance: The Marchex platform delivers actionable marketing intelligence while ensuring adherence to privacy and compliance standards, enabling healthcare organizations to balance performance visibility with patient information protection.
- Improved Decision Support: The marketing team at PDS Health connects engagement signals with appointment outcomes using Marchex's integrated systems, allowing for more informed investment decisions and improved patient experience.
See More
